Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics

scientific article published on January 1996

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1469-0691.1996.TB00212.X
P698PubMed publication ID11866824
P5875ResearchGate publication ID247640235

P50authorNiels HøibyQ12328808
Helle Krogh JohansenQ30004123
Oana CiofuQ40705960
Tacjana PresslerQ114439126
P2093author name stringChristian Koch
Niels Høiby
Oana Ciofu
Tim Jensen
P433issue2
P921main subjectPseudomonas aeruginosaQ31856
Burkholderia cepaciaQ139227
cystic fibrosisQ178194
meropenemQ421670
P304page(s)91-98
P577publication date1996-01-01
P1433published inClinical Microbiology and InfectionQ15757285
P1476titleMeropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics
P478volume2

Reverse relations

cites work (P2860)
Q36158785Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?
Q38378454Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections.
Q33975978Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis
Q40112556In Vitro Evaluation of Biofilm Dispersal as a Therapeutic Strategy To Restore Antimicrobial Efficacy.
Q35941284In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection
Q36112367Isolation of infectious cystic fibrosis patients: results of a systematic review
Q41825397Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation
Q44208493Resistance surveillance in Italy: four-year results from the MYSTIC program
Q54069097The MYSTIC (meropenem yearly susceptibility test information collection) programme.
Q35096020The pulmonary physician in critical care. Illustrative case 1: cystic fibrosis

Search more.